Rossana N. Lazcano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rossana N. Lazcano has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
17 shared publications - Aaron Shafer
The University of Texas MD Anderson Cancer Center 1 Department of Gynecologic Oncology and Reproductive Medicine Houston, Texas
10 shared publications - Adam C. ElNaggar
Natera, Inc, Austin, TX
10 shared publications - Alejandra Griselda Serrano
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
10 shared publications - Amir Anthony Jazaeri
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
10 shared publications - Anil K. Sood
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
10 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
Due to the paucity of validated cell-surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody–drug conjugate (ADC) therapy observed in patients with several solid and hematologic malignancies. Our comprehensive surfaceome profiling approach previously identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC. We tested a CADM1-targeting ADC with a tesirine payload (SG3249) in vitro in osteosarcoma, rhabdomyosarcoma, and neuroblastoma patient-derived xenograft (PDX) cell lines. In vivo, we tested six CADM1-expressing osteosarcoma PDX models. The CADM1 ADC demonstrated significant antitumor activity in vitro across the osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines. Additionally, it effectively reduced tumor volume and extended event-free survival in all six osteosarcoma PDX models tested. Notably, the CADM1 ADC achieved a major complete response in one model (OS2), complete responses in two models (OS1 and OS33), and partial responses in three models (OS9, OS17, and OS31). Based on these results, clinical development of CADM1-targeted therapies for osteosarcoma and other CADM1-expressing pediatric solid tumors may be warranted.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
Due to the paucity of validated cell-surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody–drug conjugate (ADC) therapy observed in patients with several solid and hematologic malignancies. Our comprehensive surfaceome profiling approach previously identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC. We tested a CADM1-targeting ADC with a tesirine payload (SG3249) in vitro in osteosarcoma, rhabdomyosarcoma, and neuroblastoma patient-derived xenograft (PDX) cell lines. In vivo, we tested six CADM1-expressing osteosarcoma PDX models. The CADM1 ADC demonstrated significant antitumor activity in vitro across the osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines. Additionally, it effectively reduced tumor volume and extended event-free survival in all six osteosarcoma PDX models tested. Notably, the CADM1 ADC achieved a major complete response in one model (OS2), complete responses in two models (OS1 and OS33), and partial responses in three models (OS9, OS17, and OS31). Based on these results, clinical development of CADM1-targeted therapies for osteosarcoma and other CADM1-expressing pediatric solid tumors may be warranted.
- Open Access
- 10 January 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 881-896
Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
Due to the paucity of validated cell-surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody–drug conjugate (ADC) therapy observed in patients with several solid and hematologic malignancies. Our comprehensive surfaceome profiling approach previously identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC. We tested a CADM1-targeting ADC with a tesirine payload (SG3249) in vitro in osteosarcoma, rhabdomyosarcoma, and neuroblastoma patient-derived xenograft (PDX) cell lines. In vivo, we tested six CADM1-expressing osteosarcoma PDX models. The CADM1 ADC demonstrated significant antitumor activity in vitro across the osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines. Additionally, it effectively reduced tumor volume and extended event-free survival in all six osteosarcoma PDX models tested. Notably, the CADM1 ADC achieved a major complete response in one model (OS2), complete responses in two models (OS1 and OS33), and partial responses in three models (OS9, OS17, and OS31). Based on these results, clinical development of CADM1-targeted therapies for osteosarcoma and other CADM1-expressing pediatric solid tumors may be warranted.
- 10 January 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 881-896
Open AccessIdentification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
Due to the paucity of validated cell-surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody–drug conjugate (ADC) therapy observed in patients with several solid and hematologic malignancies. Our comprehensive surfaceome profiling approach previously identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC. We tested a CADM1-targeting ADC with a tesirine payload (SG3249) in vitro in osteosarcoma, rhabdomyosarcoma, and neuroblastoma patient-derived xenograft (PDX) cell lines. In vivo, we tested six CADM1-expressing osteosarcoma PDX models. The CADM1 ADC demonstrated significant antitumor activity in vitro across the osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines. Additionally, it effectively reduced tumor volume and extended event-free survival in all six osteosarcoma PDX models tested. Notably, the CADM1 ADC achieved a major complete response in one model (OS2), complete responses in two models (OS1 and OS33), and partial responses in three models (OS9, OS17, and OS31). Based on these results, clinical development of CADM1-targeted therapies for osteosarcoma and other CADM1-expressing pediatric solid tumors may be warranted.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S2. Demographic and Clinical Characteristics for Patients Who Underwent Second Look Laparoscopy and Circulating Tumor DNA (ctDNA) Analysis
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S2. Demographic and Clinical Characteristics for Patients Who Underwent Second Look Laparoscopy and Circulating Tumor DNA (ctDNA) Analysis
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S4. Clinical Information of Translational Samples
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S4. Clinical Information of Translational Samples
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S5. Progressively Upregulated or Downregulated Genes in the Tumor Compartment of MRD+ Cases
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S5. Progressively Upregulated or Downregulated Genes in the Tumor Compartment of MRD+ Cases